Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 20/20 | 0.84 |
| ▸ | CCNE1 | P24864 | 20/20 | 0.84 |
| ▸ | CDK2 | P24941 | 20/20 | 0.84 |
| ▸ | CDK4 | P11802 | 17/20 | 0.77 |
| ▸ | CCND1 | P24385 | 17/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7987273 | 0.96 | CCNE2 (0.78) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7998067 | 0.95 | CCNE2 (0.82) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5514173 | 0.94 | CCNE2 (0.74) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7998057 | 0.93 | CCNE2 (0.73) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5514244 | 0.93 | CCNE2 (0.73) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5515006 | 0.93 | CCNE2 (0.83) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5521972 | 0.92 | CCNE2 (0.72) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL8000149 | 0.92 | CCNE2 (0.72) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7987326 | 0.92 | CCNE2 (0.71) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4024941 | 0.92 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-24 | — | — | US | claimed |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-11 | — | — | US | claimed |
| US-6593356-B2 | The present invention relates to the synthesis of a new class of indeno(1,2-c)pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and the | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | claimed |
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | claimed |
| US-7250435-B2 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-6593356-B2 | The present invention relates to the synthesis of a new class of indeno(1,2-c)pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and the | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | CCNE2 48/4885CCNE1 33/4885CDK2 9/4885 |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CDK17, CDK7 | CCNE2 50/4885CCNE1 41/4885CDK2 6/4885 |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | CCNE2 48/4885CCNE1 33/4885CDK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.